At CrownBio we are aware of the rapidly changing face of Drug Discovery, and are continually developing and refining our collections of models and services to help our clients constantly improve their Drug Discovery processes. Keep up to date with our latest research through our in depth Application Notes, with each document encompassing all aspects of CrownBio platforms and services across a specific topic. Can’t see a topic you are looking for? Contact us to find out more about how we can help you today.
CardioVascular and Metabolic Disease (CVMD)
Naturally occurring NHP obesity models are by far the most predictive animal model system for human metabolic syndrome. We provide colonies of both spontaneous and diet-induced obesity NHP models to progress your dysmetabolism research and Drug Discovery process.
Discover our collection of naturally diabetic NHPs (the most clinically translatable animal model for Type 2 diabetes research), and how our preclinical CVMD Translational Technology Platforms support your transition into the clinic.
Discover our fully comprehensive portfolio of breast cancer platforms through cell lines, Cell Line Derived Xenograft models, to highly predictive preclinical Patient-Derived Xenografts (PDXs), complemented by our suite of immuno-oncology models.
Read more on CrownBio’s generation of EGFR TKI resistant HCC827-derived cell lines and models with c-MET amplification confirmed as the resistance mechanism.
Learn about our comprehensive platform for evaluating HER2 amplified gastric cancer, including our fully integrated drug discovery resource of PDX, PDX-derived cell line, and related xenograft model.
CrownBio presents a variety of interesting and diverse mouse clinical trials, using our PDX models to accurately identify and validate biomarkers and genetic signatures of response.
Read about the CAR-T therapies, platforms of murine and human immunity, and novel systems for evaluation of targeted human-specific immunotherapeutics that make up CrownBio’s In Vivo Immunotherapy Translational Technology Platform.
Understanding the many mechanisms of drug resistance is critical to developing more effective treatment regimens. Our AppNote covers CrownBio PDX and Cell Line Derived Xenograft models of de novo resistance, as well as focusing on acquired resistance to targeted agents.
Investigate our fully comprehensive suite of prostate cancer platforms, including the development of hard-to-build PDX models.
Focusing on our collection of around 70 SCLC PDX models, we present full model characterization, validation, and in vivo pharmacology, as well as a novel SCLC HuTrial case study.
Find out why Studylog® is the best animal study workflow suite for efficiently running multiple, large, multicenter HuTrials.
CrownBio details our range of TNBC research platforms (including a collection of nearly 20 PDX models) for this high unmet need disease area.
Find out how our fully integrated Translational Oncology Platform de-risks transitioning your therapy into the clinic, from PDX selection to discovery of biomarkers and gene signatures for patient stratification.
Life Science Products
CrownBio has developed a full suite of IgG isotype controls specifically for use in in vivo animal studies and high throughput screening assays. Read more on immunogen selection, antibody analysis and purity, as well as in vivo testing.